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3Abstract
Mutations of many genes within the phosphatidylinositol-3-kinase (PI3K)-AKT-MTOR
pathway are well known causes of brain overgrowth (megalencephaly) as well as segmental
cortical dysplasia (such as hemimegalencephaly, focal cortical dysplasia and
polymicrogyria). Mutations of the AKT3 gene, in particular, have been reported in a few
individuals with these phenotypes. However, our understanding regarding the clinical and
molecular spectrum associated with mutations of this critical gene is limited, with no clear
genotype-phenotype correlations. We therefore sought to further delineate this spectrum,
study levels of mosaicism and identify genotype-phenotype correlations of AKT3 related
disorders. We performed targeted sequencing of AKT3 on patients with these phenotypes by
molecular inversion probes and/or Sanger sequencing to determine the type and level of
mosaicism of mutations. We analyzed all clinical and brain imaging data of mutation-positive
individuals including neuropathological analysis in one instance. We performed ex-vivo
kinase assays on AKT3 engineered with the patient mutations and examined the phospholipid
binding profile of Pleckstrin Homology domain localizing mutations. We identified 14 new
individuals with AKT3 mutations with several phenotypes dependent on the type of mutation
and level of mosaicism. Our comprehensive clinical characterization, and review of all
previously published patients, broadly segregates individuals with AKT3 mutations into two
groups: patients with highly asymmetric cortical dysplasia caused by the common p.E17K
mutation, and patients with constitutional AKT3 mutations exhibiting more variable
phenotypes including bilateral cortical malformations, diffuse megalencephaly without
cortical dysplasia, polymicrogyria, and periventricular nodular heterotopia. All mutations
increased kinase activity, and PH domain mutants exhibited enhanced phospholipid binding.
Overall, our study shows that activating mutations of the critical AKT3 gene are associated
with a wide spectrum of brain involvement ranging from focal or segmental brain
malformations (such as hemimegalencephaly and polymicrogyria) predominantly due to
mosaic AKT3 mutations, to diffuse bilateral cortical malformations, megalencephaly and
heterotopia due to constitutional AKT3 mutations. We also provide the first detailed
neuropathologic examination of a child with extreme megalencephaly due to a constitutional
AKT3 mutation. This child has one of the largest documented pediatric brain sizes, to our
knowledge. Finally, our data show that constitutional AKT3 mutations are associated with
megalencephaly with autism, similar to PTEN-related disorders. Recognition of this broad
clinical and molecular spectrum of AKT3 mutations is important for providing early diagnosis
and appropriate management of affected individuals, and will facilitate targeted design of
future human clinical trials using PI3K-AKT pathway inhibitors.
4Introduction
Mutations of multiple genes within the phosphatidylinositol-3-kinase (PI3K)-AKT-MTOR
pathway are well known causes of brain overgrowth (megalencephaly) as well as segmental
cortical dysplasia (such as hemimegalencephaly, focal cortical dysplasia and polymicrogyria)
(Mirzaa et al., 2013). Mutations of the AKT3 gene have been reported in eleven patients to
date, including seven with constitutional mutations causing the megalencephaly-
polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome (Riviere et al., 2012;
Nakamura et al., 2014; Harada et al., 2015; Jamuar et al., 2014; Nellist et al., 2015; Negishi et
al., 2017), and four with the mosaic p.E17K mutation causing hemimegalencephaly (Poduri
et al., 2012; Riviere et al., 2012; Lee et al., 2012; Jansen et al., 2015;). However, our
understanding regarding the clinical and molecular spectrum associated with mutations of
this critical gene is limited, with no clear genotype-phenotype correlations. We therefore
sought to further delineate this spectrum, study levels of mosaicism and identify genotype-
phenotype correlations of AKT3 related disorders. Here, we report 14 additional patients with
AKT3 mutations, including four with novel mutations, who have more diverse phenotypes
including bilateral perisylvian polymicrogyria, bilateral periventricular nodular heterotopia,
and megalencephaly with autism but without any cortical dysplasia. We further provide the
first detailed neuropathologic characterization of extreme megalencephaly caused by a
constitutional AKT3 mutation in a previously reported child (Riviere et al., 2012). This child
has one of the largest documented brain sizes in the pediatric population, to our knowledge.
We also report on the first child with bilateral multifocal cortical dysplasia caused by the
mosaic E17K mutation that was detectable in skin-derived DNA. Our report substantially
expands the clinical, molecular and biochemical spectrum of AKT3 related disorders and
shows that activating mutations of this critical gene are associated with a broader spectrum of
developmental brain disorders. Knowledge of this spectrum has important implications for
the clinical and molecular diagnosis of affected individuals, recurrence risk counseling, and
design of future human clinical trials using PI3K-AKT-MTOR pathway inhibitors.
Materials and methods
Human subjects and samples. The Institutional Review Board at Seattle Children’s
Hospital approved this study. Individuals with megalencephaly and focal malformations of
cortical development were enrolled as part of the developmental brain disorders research
project. Informed consent was obtained from subjects prior to enrollment in the study.
Genomic DNA was extracted from various tissues (blood, saliva, skin fibroblasts, brain)
using standard protocols. Brain tissue was obtained during clinically indicated epilepsy
surgery and appropriate samples were analyzed by our molecular methods.
Brain Magnetic Resonance Imaging. All subjects underwent brain magnetic resonance
(MR) imaging as part of their routine clinical care. The investigators reviewed all images and
all relevant clinical and phenotypic data.
Statistics. p values were calculated by use of Fisher’s exact test. A P value less than 0.05
was considered statistically significant.
Molecular methods. Multiplex targeted sequencing using smMIPs. We designed a pool of
26 smMIPs oligonucleotide probes targeting the coding sequences of AKT3. smMIPs tiled
across a total of 2937 bp of genomic sequence, including 100% of the 1498 coding base pairs
(bp) of AKT3. 100 ng capture reactions were performed in parallel. Massively parallel
5sequencing was performed on an Illumina HiSeq system. Variant analysis was performed
using our previously published pipeline (Mirzaa et al., 2016a). All missense, nonsense and
splice site variants seen in two or more capture events that had a frequency <1% in public
databases were retained for analysis.
Sanger sequencing. We performed confirmation of constitutional mutations by direct Sanger
sequencing. PCR amplification was done with 50 ng of genomic DNA using Taq DNA
polymerase (Applied Biosystems, Carlsbad, CA, USA). Primers used to amplify the coding
and flanking non-coding regions of AKT3 were designed using Primer 3. Double-stranded
DNA sequence analysis was done with the BigDye Terminator chemistry (Applied
Biosystems), and reactions were run on the ABI 3730_l Genetic Analyzer (Applied
Biosystems). Sequence chromatograms were analyzed with Mutation Surveyor software
version 3.30. Sequences were compared with normal control samples and the reference
sequences for AKT3.
Overgrowth Next Generation Sequencing (NGS) panel v.1. This is multiplex PCR panel
followed by NGS performed on Ion Torrent PGM platform. Allele detection limit was 1% at
1000X and 10% at 200X coverage. The threshold for mutation detection was set at 10X
without strand bias.
Cell culture. HEK293 cells were grown at 370C in 5% CO2 in DMEM supplemented with
10% fetal calf serum, L-GLN and antibiotics (pen-strep).
Expression vector, site-directed mutagenesis, transfection and
immunoprecipitation. AKT3 expression vector was obtained from Origene (RC221051)
as pCMV6-FLAG-MYC tagged Human cDNA ORF Clone containing AKT3 (NM_005465).
Patient mutations were introduced using the QuikChange® Site-Directed Mutagenesis Kit
(200518) from Agilent Technologies (Stratagene) using custom-designed primer pairs
(Supplementary Table 1). AKT3 containing plasmids were expressed and transfected into
HEK293 cells using calcium phosphate. Briefly, 5µg of DNA was added to 61µl of 2M
CaCl2 in 500µl ddH2O. This was added drop wise to 500µl of 2x HBS (NaCl, Na2HPO4,
HEPES pH to 7.0) before adding to adherent cells, which were harvested 48 hours later.
Protein extracts were prepared by incubating the cell pellet on ice (1 hr) in detergent
extraction buffer (50mM Tris.HCl pH7.5, 150mM NaCl, 2mM EDTA, 2mM EGTA, 50mM
NaF, 25mM β-glycerolphosphate, 0.1mM Na-orthovanadate, 0.2% Triton-X100, 0.3% 
IGEPAL with protease inhibitor cocktail (Roche)). Insoluble material was precipitated by
centrifugation at 40C and the supernatant used for immunoprecipitation. Ectopically
expressed FLAG-tagged AKT3 was then immunoprecipitated using ANTI-FLAG® M2
Affinity Gel (A2220, Sigma-Aldrich) according to manufacturers’ instructions.
Kinase assay. AKT3 specific kinase assay using FLAG-captured ectopically expressed
AKT3 was assessed using the Nonradioactive AKT Kinase Assay Kit (9840) from Cell
Signaling Technology according to manufacturers’ instructions, utilizing phospho-GSK-3α/β 
(Ser21/9) (37F11) rabbit mAb (9327) and mouse monoclonal ANTI-FLAG® M2 antibody
(F3165) from Sigma-Aldrich.
Phosphoinositide dot blot binding analysis. FLAG immunoprecipitated AKT3 was
eluted from the FLAG beads using FLAG peptide (3X FLAG® Peptide, F4799 Sigma-
Aldrich). PIP Strip membranes were incubated with purified AKT3 protein in 5mls of PBS-T
3%BSA according to manufacturer’s instructions (P-6001 PIP STRIPS and P-6100 PIP
6Array, Echelon Biosciences). Binding was detected by incubation with mouse monoclonal
ANTI-FLAG® M2 antibody with chemiluminesence detection.
Results
Clinical results. We identified AKT3 mutations in 14 new, and four previously reported,
subjects, who collectively demonstrate a wide spectrum of features (Jansen et al., 2015;
Nellist et al., 2015; Riviere et al., 2012). The clinical and molecular data of our 13 new
mutation-positive children, as well as the previously published nine patients, are summarized
in Table 1. The neuroimaging features of these children are shown in Fig. 1. More
comprehensive clinical, neuroimaging and molecular data provided in Supplementary
Tables 2-5.
Neuroimaging features. First, we identified the mosaic p.E17K AKT3 mutation in three
children. The first child (LR15-262) had hemimegalencephaly with contralateral
hemimicroencephaly (Fig. 1A-B), and several cutaneous capillary malformations. This child
was born in status epilepticus, had early onset intractable epilepsy, and underwent
hemispherectomy at age two weeks. The second patient (LR16-251) harboring the p.E17K
mutation had a distinctive phenotype characterized by megalencephaly with multifocal but
bilateral cortical dysplasia (Fig. 1C-D). This child had intractable epilepsy and passed away
at the age of 10 months due to his deteriorating neurologic status. He also had three capillary-
lymphatic malformations. The third child (LR11-443) had a massively enlarged and
dysplastic cerebral hemisphere with dysplasia identified in the contralateral hemisphere as
well. She also had a distinctive vascular malformation on the lower leg characterized by cutis
marmorata telangiectatica congenita (or CMTC) (Jansen et al., 2015).
Second, we identified constitutional AKT3 mutations in the remaining 14 patients who can be
clinically segregated into three groups. The first group includes children with
megalencephaly and polymicrogyria (PMG) (N = 6). These children had bilateral perisylvian
polymicrogyria with variable ventriculomegaly (Fig. 1K-R). Among this group, one child
had hydrocephalus requiring neurosurgical shunting and Chiari malformation requiring
posterior fossa decompression (LR14-254; Fig. 1O-P). This child showed global
psychomotor delay at two years of age (due to mainly langue and motor delays). However, on
preschool evaluation at age six years, he showed normal cognitive skills (Wechsler Preschool
and Primary Scale of Intelligence, WPPSI, score =92). The second group consists of children
with megalencephaly and diffuse cortical dysplasia (also termed dysplastic megalencephaly,
or DMEG) with diffuse and bilateral periventricular nodular heterotopia, a rare subgroup not
previously associated with any genes (N=3) (Fig. 1G-J, W-X). Patients LR16-301 and LP96-
103 had extensive heterotopia all along the ventricular surface (Fig. 1G-J), whereas patient
LR14-112 had fewer and more discrete heterotopia (Fig. 1W-X). Interestingly, all three
patients within this group had moderate to severe ventriculomegaly. The third group of
children with constitutional mutations had megalencephaly with no or subtle (often
unilateral) cortical malformations and variable ventriculomegaly (N = 4) (Fig. 1E-F, S-V).
One child within this group had megalencephaly, mildly thick corpus callosum and very
subtle cortical dysplasia with unilateral prominent in cortical infolding into the perisylvian
region (LR12-470, Fig. 1, S-T). This child had mild learning issues and communication
problems. Another child within this group (LR13-008) was formally diagnosed with Autism
Spectrum Disorders (ASD). Finally, one child (LR17-XXX) within this group as well had
megalencephaly alone with normal tone, and no developmental or neurologic issues at age
three years (Supplementary Data).
7Neuropathologic abnormalities. We examined the neuropathologic features of
megalencephaly-associated polymicrogyria in a previously reported AKT3 mutation-positive
child (LR08-018) who died unexpectedly at age six years. This boy had congenital
megalencephaly, bilateral perisylvian polymicrogyria, cerebellar tonsillar ectopia, somatic
asymmetry and connective tissue dysplasia (Mirzaa et al., 2012). He was identified to have a
de novo p.R465W mutation in AKT3 (Riviere et al., 2012). This child passed away during
sleep presumably due to Sudden Unexpected Death in Epilepsy (SUDEP) (further details
provided in the Supplementary Text). Neuropathologic analysis on postmortem brain tissue
revealed that his brain weighed twice the normal weight of adult brains (total weight = 2313
gms) and was asymmetrically enlarged (Fig. 2A-B). There was evidence of diffuse cortical
dysplasia with irregular hyperconvoluted gyri suggestive of diffuse polymicrogyria, including
anomalous branching and fusion of gliotic layer 1. There were also increased numbers of
neurons in layer 6 and within the white matter that appeared disorganized and maloriented.
However, neurons were not strikingly enlarged or dysplastic, and no balloon cells were
identified. The hippocampus was grossly small and gliotic, and the dentate gyrus exhibited
focal “tram-track” splitting of the granule cell layer, typically associated with chronic
epilepsy (Fig. 2B-Q).
Somatic features. Several children in this series had vascular malformations including cutis
marmorata telangiectatica congenita (LR11-443), capillary malformations and/or prominent
veins (N = 4), and connective tissue abnormalities including aplasia cutis congenita (N = 2).
One child (LR13-008) had a prenatal stroke due to occlusion of the right cerebral artery, with
no evidence of thrombophilia. Several patients had endocrine issues including recurrent
hypoglycemia (N = 2) and hypothyroidism (N = 1). Other notable features include
immunologic issues including recurrent infections (N = 2). In one of these patients (LR14-
112), recurrent infections were due to combined IgA and IgE deficiency. Patient LR13-008
also had severe vitamin A malabsorption (Supplementary Table 4).
Molecular results. All 14 AKT3 mutations reported in this series, and our previously
reported four mutations, were identified or confirmed by targeted Next Generation and/or
Sanger sequencing. Levels of mosaicism, tissues tested and methods of detection are
provided in Supplementary Table 5. Mutations in two children with megalencephaly and
megalencephaly with heterotopia (LR16-372 and LR16-301) were identified by clinical
whole exome sequencing (WES) on the proband, followed by targeted parental mutation
analysis by Sanger sequencing.
The p.E17K mutation detected in our three patients was low-level mosaic, as mentioned
previously. In LR15-262, the alternate allele percentage (AAP) was 12.6-13.9% in affected
brain tissue from the more dysplastic hemisphere resected during epilepsy surgery.
Interestingly, the mutation was detectable in skin fibroblasts from normal-appearing skin (at
8.6-9.5% AAP) but was undetectable in peripheral blood-derived DNA. The mutation in
patient LR11-443 was present in 20-36% of cells from several affected brain regions form the
more severely affected hemisphere. It was also detectable at a very low level (1.3% of alleles)
from skin fibroblast-derived DNA (also from healthy-appearing skin). In LR16-251 who had
bilateral multi-focal cortical dysplasia, the p.E17K mutation was present at a very low level
in skin fibroblasts (AAP 1.8%). This child did not undergo epilepsy surgery due to his
bilateral malformations, and no postmortem brain tissue was available for molecular analysis.
The other AKT3 mutations identified in our series were all constitutional, and were confirmed
to be de novo when parental DNA was available. Five novel constitutional AKT3 mutations –
8p.N53L, p.F54Y, p.V268A, p.D322N, and p.W79C – were detected in five children in this
series. Mutations in two patients (LR12-470 and LR13-008) are presumed to be constitutional
as DNA derived from saliva was used for molecular analysis, and peripheral blood-derived
DNA was unavailable.
Functional analysis of AKT3 mutants. With the exception of p.R465W, which localizes
to the C-terminal region of AKT3, the remaining mutations were found in the Pleckstrin
homology (PH) domain or the catalytic kinase domain (Fig. 3A). Kinase activity analysis
following ectopic over-expression clearly showed that all identified patient mutations caused
increased activity compared to wild-type (WT) AKT3 (Fig. 3, B-C). The p.E17K PH mutant
domain has previously been shown to result in elevated kinase activity and to be oncogenic
via enhanced pathological localization to the plasma membrane (Carpten et al., 2007; Parikh
et al., 2012). As the PH domain is critical for phospholipid binding and consequent kinase
activation, we assessed whether the novel mutations localized in the PH domain described
here (p.N53K and p.F54Y) have a similar impact upon phospholipid binding as p.E17K
(Parikh et al., 2012; Park et al., 2008). We employed dot-blot analysis using an array of
different phospholipids immobilized on WT AKT3. Indeed, these PH mutant domains
exhibited markedly elevated binding to phosphatidylinositol (3,4) biphosphate (PtdIns(3,4)P2)
in particular, which is a key plasma membrane constituent and substrate of
phosphatidylinostitol-3-kinase.
Discussion
Malformations of cortical development (MCDs) comprise a wide range of disorders
characterized by aberrant neuronal migration, proliferation and organization, and result in
significant childhood morbidity and mortality (Barkovich et al., 2012). A growing spectrum
of these malformations is now known to be caused by germline or mosaic mutations of genes
within the PI3K-AKT-MTOR signaling network (Jamuar et al., 2014; Mirzaa et al., 2013;
Mirzaa and Poduri, 2014). The post-zygotic (mosaic) mutations are most readily identified in
affected (surgically removed) brain tissues (Mirzaa et al., 2016b).
AKT3 is one of three AKT homologues (AKT1,2,3), the central effector of the PI3K-AKT-
MTOR pathway (Yang et al., 2004). Mutations of AKT1 and AKT2 have been identified in
somatic overgrowth disorders such as Proteus syndrome and in somatic overgrowth with
hypoglycemia, respectively (Hussain et al., 2011; Lindhurst et al., 2011). Reported children
with these phenotypes to date all harbored the p.E17K mutation in these respective genes.
The paralogous mutation in the brain-enriched isoform, AKT3, has been identified in mosaic
form in children with hemimegalencephaly (HMEG) (Jansen et al., 2015; Poduri et al., 2012).
Constitutional mutations of AKT3 have been identified in children with diffuse
megalencephaly in syndromic forms such as the megalencephaly-polymicrogyria-
polydactyly-hydrocephalus (MPPH) syndrome, and somatic duplications of the AKT3 locus
have been identified in a few children with HMEG and diffuse megalencephaly (MEG)
without cortical dysplasia (Chung et al., 2014; Conti et al., 2015; Hemming et al., 2016;
Wang et al., 2013). To date, only nine children (with four mutations) have been reported with
AKT3 mutations. Here, we report on the clinical and neuroimaging spectrum of 13 children
identified to have constitutional or mosaic AKT3 mutations, including five children with four
novel AKT3 mutations, adding to our previously published data on four AKT3 mutation-
positive children (Jansen et al., 2015; Nellist et al., 2015; Riviere et al., 2012). Using in vitro
kinase assay, we show that these mutations constitutionally activate AKT3.
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mutations associated with this critical gene. First, our series shows that there are important
and emerging genotype-phenotype correlations of AKT3 mutations whereby highly mosaic
p.E17K mutation is associated with very segmental brain malformations (i.e. HMEG),
whereas constitutional mutations are associated with more widespread cortical malformations
with bilateral (but often asymmetric) findings. We describe two new patients with the
recurrent, mosaic p.E17K mutation. Importantly, one of these children had a novel phenotype
characterized by multifocal and bilateral focal cortical dysplasia lacking a severity gradient
between right and left hemispheres, unlike all previously reported children with the E17K
AKT3 mutation who had highly asymmetric cortical dysplasia (regarded as “classic
hemimegalencephaly”). Second, our series substantially broadens the clinical spectrum of
constitutional AKT3 mutations to include diffuse, most often perisylvian, polymicrogyria
(PMG) and periventricular nodular heterotopia (PNH), with hydrocephalus and cerebellar
tonsillar ectopia occurring in a subset of individuals. Therefore, this report presents AKT3
mutations as the first genetic cause of MEG with PNH and PMG; a clinical phenotype
previously reported as a distinct entity (Wieck et al., 2005). Importantly, our series further
shows that constitutional AKT3 mutations, which can also occur in the PH domain where
p.E17K mutation localizes, are associated with diffuse MEG without cortical malformations,
with normal cognitive development in one patient who had autistic features – resembling the
PTEN-hamartoma tumor syndrome and suggesting that mutations of the AKT3 gene are
associated with Autism Spectrum Disorders (ASD).
Collectively our data suggest that there are several distinct brain malformation syndromes
caused by AKT3 mutations that can be broadly categorized into: (1) highly segmental cortical
dysplasia (including HMEG) and vascular malformations associated with the mosaic E17K
AKT3 mutation. We believe that this comprises a clinically recognizable subgroup with
MEG, extensive focal cortical dysplasia (either HMEG or bilateral, multifocal FCD), and
cutaneous vascular malformations; (2) MEG-PMG with frequent asymmetry and occasionally
patchy somatic findings (as occurs in MPPH syndrome); (3) MEG-PMG with periventricular
nodular heterotopia (PNH); and (4) MEG with normal or minimal cortical dysplasia, and
ASD or autistic features (Fig. 4). We believe this clinical stratification is diagnostically
important as resection of epileptic brain tissue is likely to be clinically warranted for children
in group 1, but less likely in groups 2-3. Hydrocephalus and Chiari malformations, on the
other hand, are complications likely to occur in children with diffuse MEG occurring in
groups 2-3, depending on the severity of ventriculomegaly and cerebellar tonsillar
enlargement, respectively.
Seizures are a common feature of our cohort and have been reported in Akt mouse models
with activating Akt3 mutations (Baek et al., 2015; Tokuda et al., 2011). Seizures are
especially severe in children with the E17K mutation, likely due to the severity of the
underlying cortical malformation. However, one of our patients (LR08-018) with the
constitutional R465W AKT3 mutation had intractable epilepsy as well, and may have had
SUDEP; an interesting association that suggests that aggressive anti-epilepsy treatment and
management may be necessary this spectrum. This association will require further
investigation in future children identified to have AKT3 mutations.
With regards to non-neurologic findings, our series shows that vascular malformations (VM)
are common with AKT3 related disorders and may provide useful diagnostic clues. VM in all
AKT3 mutation patients reported to date were patchy, few, and best characterized as capillary
malformations, although one patient (LR11-443) had cutis marmorata telangiectatica
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congenita (CMTC), which is clinically distinct from capillary malformations. Unlike
PIK3CA related disorders, these VMs were not associated with marked somatic overgrowth,
lipomatosis, or soft tissue hypertrophy (Keppler-Noreuil et al., 2015; Mirzaa et al., 2016a).
The occurrence of a prenatal stroke in one child is clinically noteworthy, as prenatal strokes
and/or thrombophilia have been reported in some children with the megalencephaly-capillary
malformation syndrome (MCAP) caused by PIK3CA mutations, as well as in Proteus
syndrome caused by AKT1 mutations (Mirzaa et al., 2012; Slavotinek et al., 2000).
Two children in our series also had hypoglycemia. These data add to a previous report of
hypoglycemia with AKT3 related disorders and further support this gene’s roles in glucose
regulation (Nellist et al., 2015). Mutations of AKT2 are known to cause asymmetric
overgrowth with hypoglycemia, exemplifying the critical role of this gene in insulin-
dependent glucose regulation (Arya et al., 2014; Cho et al., 2001; Garg et al., 2015; Hussain
et al., 2011). While the cause of hypoglycemia in our patients remains undetermined, this
potential association warrants further studies as this may have important clinical implications
for AKT3 mutation-positive children identified in the future as well.
Our functional analysis of each of the patient mutations showed a robust elevation of catalytic
kinase activity. This is consistent with the elevated PI3K-AKT-MTOR signaling underlying
these types of brain overgrowth disorders. Furthermore, PH domain-localizing mutations all
exhibited elevated phospholipid binding compared to wild type (WT). This feature of the
p.E17K mutation has been proposed to explain why this mutation is oncogenic and recurrent
in a wide range of cancers (Carpten et al., 2007). Considering the similar phospholipid
binding profile, we have uncovered here for p.N53K and p.F54Y compared to p.E17K, our
findings suggest that careful monitoring of such individuals in particular for cancers is
warranted, although formal cancer surveillance guidelines cannot be proposed at this time
due to lack of clinical evidence of these complications.
In summary, we show that activating mutations of AKT3 are associated with a much broader
spectrum of developmental brain disorders in children, with several clinical phenotypes
determined partially by the type of mutation and level of mosaicism. Our series suggests that
the mosaic E17K AKT3 mutation is associated with highly segmental brain malformations
that may warrant surgical resection to achieve seizure control, whereas constitutional
mutations of AKT3 are associated with bilateral brain malformations including bilateral
perisylvian polymicrogyria, periventricular nodular heterotopia and megalencephaly without
cortical dysplasia. In this series, we also report on the neuropathologic abnormalities caused
by a constitutional AKT3 mutation in one of the largest documented brain sizes in the
pediatric population. Our data also suggest that monitoring for hypoglycemia in affected
individuals may be warranted as well.
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Tables
Table 1. Summary of the clinical and molecular findings of AKT3 mutation-positive patients (N=24) [AKT3: NM_005465.4]
Subject ID Diagnosis cDNAchange Amino acid change Functional domain Inheritance
Mutation type, AAP
(tissue)
Mosaic AKT3 mutations (N=5)
LR15-262 DMEG/HMEG c.49G>A p.Glu17Lys PH NA Mosaic, ~8-14% (brain, skin)
HME-1565
(Lee et al.,
2012)
HMEG c.49G>A p.Glu17Lys PH De novo Mosaic, ~16-30% (brain)
Patient 3
(Poduri et al.,
2012)
DMEG/HMEG c.49G>A p.Glu17Lys PH De novo Mosaic, 35% (brain)
LR11-443
(Jansen et al.,
2015)
DMEG/HMEG c.49G>A p.Glu17Lys PH De novo Mosaic, 1-18% (brain, skin)
LR16-251 DMEG/multifocal c.49G>A p.Glu17Lys PH NA Mosaic, 1.8% (skin)
Constitutional AKT3 mutations (by functional domain; N=19)
Patient
(Takagi et al.,
2017)
MEG c.118G>A p.Glu40Lys PH De novo Constitutional
LR16-372 MEG c.159C>A p.Asn53Lys PH De novo Constitutional
LR16-301 MEG-PMG-PNH c.161T>A p.Phe54Tyr PH De novo Constitutional
LR17-XXX MEG c.237G>T p.Trp79Cys PH De novo Constitutional
LP96-103 MEG-PMG-PNH c.548T>A p.Val183Asp Kinase De novo Constitutional
LR12-314
(Nellist et al.,
2015)
MEG-PMG-PNH c.548T>A p.Val183Asp Kinase De novo Constitutional
LR11-354
(Riviere et al.,
2012)
MEG-PMG c.686A>G p.Asn229Ser Kinase De novo Constitutional
Patient
(Harada et al.,
2015)
MEG-PMG c.686A>G p.Asn229Ser Kinase De novo Presumed constitutionala
Patient 2
(Nakamura et
al., 2014)
MEG-PMG [MCAP] c.686A>G p.Asn229Ser Kinase De novo Constitutional
13
Patient 1
(Negishi et al.,
2014)
MEG-PMG c.686A>G p.Asn229Ser Kinase De novo Constitutional
LR13-041 MEG-PMG c.803T>C p.Val268Ala Kinase De novo Presumed constitutionala
LR14-271 MEG-PMG c.964G>A p.Asp322Asn Kinase De novo Constitutional
LR14-254 MEG-PMG c.964G>A p.Asp322Asn Kinase De novo Constitutional
LR12-412 MEG-PMG c.1393C>T p.Arg465Trp C-terminal NA Constitutional
LR14-025 MEG-PMG c.1393C>T p.Arg465Trp C-terminal De novo Constitutional
LR12-470 MEG c.1393C>T p.Arg465Trp C-terminal De novo Presumed constitutionala
LR13-008 MEG-autism c.1393C>T p.Arg465Trp C-terminal De novo Presumed constitutionala
LR14-112 MEG-PMG-PNH c.1393C>T p.Arg465Trp C-terminal De novo Constitutional
LR08-018
(Riviere et al.,
2012)
MEG-PMG c.1393C>T p.Arg465Trp C-terminal De novo Constitutional
PMG-3801
(Jamuar et al.,
2014)
MEG-PMG c.1393C>T p.Arg465Trp C-terminal De novo Constitutional
Abbreviations: AAP, alternative allele percentage (i.e. mutation level); DMEG, dysplastic megalencephaly; HMEG, hemimegalencephaly; MEG,
megalencephaly; MPPH, megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome; NA, not available; PNH, periventricular nodular
heterotopia; PMG, polymicrogyria.
aMutations are presumed to be constitutional or germline due to one tissue only being analyzed, with no evidence of mosaicism in the analyzed
tissue
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Figures and figure legends
Figure 1. Brain MRIs of AKT3 mutation-positive children. A-B, Brain MR images of patient
LR15-262 showing markedly enlarged and dysplastic right cerebral hemisphere with diffuse
cortical dysplasia and dysmyelination consistent with hemimegalencephaly. The contralateral
hemisphere is markedly decreased in size with areas of cortical dysplasia (hemimicroencephaly);
C-D, images of patient LR16-251 showing multifocal areas of dysplastic cortex in the
perisylvian, frontal, temporal and occipital regions (arrows); E-F, images of patient LR16-372
showing a thick and dysplastic corpus and deeply in folded perisylvian regions; G-I, images of
patient LR16-301 showing striking megalencephaly, ventriculomegaly, stretched but thick
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corpus callosum, diffuse polymicrogyria with deep in folding in the right occipital lobe, and
bilateral periventricular nodular heterotopia (arrowheads); J, image of patient LP96-103 showing
diffuse bilateral perisylvian polymicrogyria, ventriculomegaly, cavum septum pellucidum et
vergae and diffuse periventricular nodular heterotopia (arrowheads); K-L, images of patient
LR13-041 showing a large cerebellum with cerebellar tonsillar ectopia, bilateral polymicrogyria
predominantly in the perisylvian region (more severe on the right, arrows) with dysmyelination;
M-N, images of patient LR14-271 showing diffuse megalencephaly with a thick corpus callosum
and deep infolding in the perisylvian region suggestive of polymicrogyria (arrows); O-P, images
of patient LR14-254 showing diffuse megalencephaly, thick corpus callosum and bilaterally
diffuse infolding of the perisylvian region suggestive of polymicrogyria (arrows); Q-R, images
of patient LR14-025 showing megalencephaly, thick corpus callosum and bilateral diffuse
polymicrogyria with increased extra-axial space; S-T, images of patient LR12-470 showing
megalencephaly and thick corpus callosum. This patient also had deep infolding in the right
perisylvian region suspicious for polymicrogyria, with very limited involvement (arrows); U-V,
images of patient LR13-008 showing diffuse megalencephaly and possible area of cortical
dysplasia in the right perisylvian region; W-X, images of patient LR14-112 showing diffuse
megalencephaly, bilateral perisylvian polymicrogyria and bilateral ventriculomegaly.
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Figure 2. Pathologic examination of the brain of patient LR08-018 (p.R465W).
A, Brain size. Graph depicting the largest pediatric brain sizes (in grams) previously reported in
the literature (green bars) in relationship to the brain size of patient LR08-018 (with the
p.R465W mutation, red bar) demonstrating that brain size for this patient is markedly larger than
these patients (Wilson, 1934). The graph is an adaptation of the human brain growth diagram
from the Smithsonian Institute (http://humanorigins.si.edu/human-characteristics/brains). The
graph shows the periods of rapid brain growth (in orange) plus the period of decreased brain
growth (in blue) followed by the plateau in brain growth.
B-E, Cerebral hemispheres. The massive brain (2313 g; approximately twice normal weight for
age) was asymmetrically enlarged. The left hemisphere (B, C) weighed 941 g, and the right (D,
E) weighed 1128 g. Primary fissures such as the Sylvian (sy), central (ce), postcentral (pc), and
calcarine (ca) sulci were recognizable, but secondary and tertiary sulci were abnormal. Gyri
appeared irregular and overall hyperconvoluted. The corpus callosum was present including genu
(ge), body, and splenium (sp). The anterior commissure (ac) was present but small. White
asterisks: artefactual disruption of hemispheres due to brain removal and transport. Black
asterisks: torn junction of hemispheres and midbrain. All panels at same magnification.
F-I. Hyperconvolution and polymicrogyria in cerebral cortex. (F) Brain slice through parietal
cortex showed redundant folds of cortex extending deep into white matter. (G) Histological
section (H&E) through the same region showed relatively sharp gray-white junctions. (H)
Inferior temporal cortex exhibited features of polymicrogyria, including anomalous branching
and fusion of gliotic layer 1 (GFAP immunohistochemistry). (I) Layer 1 fusion and branching
were confirmed by NeuN immunohistochemistry.
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J-N. Abnormal layering of cerebral cortex, and excessive white matter neurons. In foci not
involved by polymicrogyria, such as right posterior perisylvian cortex, cortical layering was
moderately disorganized. (J) Cortical layers were identified based on cell size and density. NeuN
immunohistochemistry. (K) Layer 1 was cell-sparse and contained only small neurons. (L) Layer
4 contained typical small (granular) neurons. (M) Layer 6 neurons were particularly disorganized
and maloriented. (N) Increased neurons in white matter (wm). Interestingly, neurons in this case
were not strikingly enlarged or dysplastic, nor were any balloon cells present.
O-Q. Hippocampal and brainstem abnormalities of patient LR08-018. (O) The left
hippocampus was very small and gliotic, and the hippocampal sulcus (arrowhead) was open,
suggesting a deficiency of perforant pathway fibers, which would normally cross the fused
sulcus. GFAP immunohistochemistry. (P) Histologically, the dentate gyrus exhibited focal
"tram-track" splitting of the granule cell layer (arrowhead; enlarged 2X in inset), a finding
usually associated with chronic epilepsy. (Q) The upper medulla showed marked asymmetry of
the pyramidal tract, essentially limited to one side (arrowhead). The adjacent inferior olives were
moderately hypoconvoluted. H&E.
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Figure 3. Analysis of AKT3 activity in vitro.
A, The primary structure of AKT3 showing the relative positions of the Pleckstrin Homology
(PH) domain for lipid binding the catalytic kinase domain and C-terminal (C-ter) region.
Mutations identified to date are shown along with the numbers of patients with these mutations
in brackets. Abbreviations: DMEG, dysplastic megalencephaly; HMEG, hemimegalencephaly;
MEG, megalencephaly; MPPH, megalencephaly-polydactyly-hydrocephalus (MPPH) syndrome.
B, Catalytic kinase domain and C-terminal localizing patient-derived AKT3 mutations are
associated with elevated kinase activity. Ectopically expressed wild-type (WT) AKT, a kinase
dead variant K177M, the E17K activating PH domain mutant and various patient mutants were
assessed for kinase activity using a GSK3β peptide as a substrate in an ex vivo kinase assay. The
upper panel shows immune detection of phosphorylated GSK3β peptide following western 
blotting with anti-phospho-GSK3β (Ser9/Ser21) antibody. The patient mutants all exhibit 
elevated phospho-activity compared to WT. The graph depicts quantitation of phospho-GSK3β 
(Ser9/Ser21) signal (a.u. arbitrary units). Error bars represent mean + SD (n=4), p-values were
determined using Student’s t-test.
C, PH domain localizing patient mutations are associated with elevated kinase activity and
altered phospholipid-binding profile. Left-hand panels show western blot analysis of phospho-
GSK3β (Ser9/Ser21) of ectopically expressed wild-type (WT), K177M kinase dead and three PH 
domain patient mutants; E17K, N53K and F54Y. The graph depicts quantitation of phospho-
GSK3β (Ser9/Ser21) signal (a.u. arbitrary units). Error bars represent mean + SD (n=4), p-values 
were determined using Student’s t-test.
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The bottom panels depict PIP-membranes seeded with various lipids and phospholipids for dot
blot binding analysis. Ectopically expressed FLAG-tagged WT and AKT3 PH domain mutants
were incubated with the PIP Strips and bound protein detected by western blotting using anti-
FLAG. All three PH domain mutants exhibit altered and elevated binding to specific
phospholipids compared to WT. LPA; Lysophophatidic acid, S1P: Sphingosine-1-phosphate,
LPC; Lysophosphocholine, PtdIns; Phosphatidylinositol, P; phosphate, PE;
Phosphatidylethanolamine, PA; Phosphatidic acid, PS; Phosphatidylserine, PC;
Phosphatidylcholine.
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Figure 4. Diagram showing the spectrum of AKT3 associated phenotypes. Several groups of
partially overlapping developmental brain disorders are associated with AKT3 mutations that
include the following phenotypes (1) focal malformations of cortical development that are highly
segmental (e.g. FCD, HMEG, DMEG; orange); (2) bilateral polymicrogyria (PMG, dark purple)
with or without ventriculomegaly or hydrocephalus (VMEG-HYD; light purple), and heterotopia
(HET; blue); (3) diffuse megalencephaly (MEG) with intellectual disability (ID) and/or Autistic
features (AUT) with subtle or no cortical dysplasia (green). *Of note, the megalencephaly-
capillary malformation syndrome (MCAP) and the megalencephaly-polymicrogyria-polydactyly-
hydrocephalus syndrome (MPPH) fit within the second group of AKT3 related disorders, from
the brain phenotype perspective. MCAP can be further clinically distinguished by somatic
findings (somatic overgrowth, vascular or lymphatic abnormalities), and MPPH by the
occurrence of polydactyly in a subset of affected individuals.
Abbreviations: AUT, autism; DMEG, dysplastic megalencephaly; FCD, focal cortical
dysplasia; HET, heterotopia; HMEG, hemimegalencephaly; HYD, hydrocephalus; PMG,
polymicrogyria; VMEG, ventriculomegaly.
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Supplementary Table 1. Primer pairs used for site-directed mutagenesis
AKT3 mutation Forward Primer Reverse Primer
E17K 5'
GGTTGGGTTCAGAAGAGGGGAAAATATATAAAAAACTGGAGG
3'
5' CCTCCAGTTTTTTATATATTTTCCCCTCTTCTGAACCCAACC 3'
N53K 5' CTTATCCCCTCAACAAGTTTTCAGTGGCAAAATG 3' 5' CATTTTGCCACTGAAAACTTGTTGAGGGGATAAG 3'
F54Y 5' CTTATCCCCTCAACAACTATTCAGTGGCAAAATGCC 3' 5' GGCATTTTGCCACTGAATAGTTGTTGAGGGGATAAG 3'
V183D 5’ GAAGAAAGAAGACATTATTGCAAAGG 3‘ 3' CCTTTGCAATAATGTCTCTTCTTTCTTC5‘
N229S 5' GATGGAATATGTTAGTGGGGGCGAGCTG 3' 5' CAGCTCGCCCCCACTAACATATTCCATC 3'
V268A 5' CATTCCGGAAAGATTGCGTACCGTGATCTCAAG 3' 5' CTTGAGATCACGGTACGCAATCTTTCCGGAATG 3'
D322N 5' GGTGTTAGAAGATAATAACTATGGCCGAGCAG 3' Rev: 5' CTGCTCGGCCATAGTTATTATCTTCTAACACC 3'
R465W 5' GACAATGAGAGGTGGCCGCATTTCCC 3' 5' GGGAAATGCGGCCACCTCTCATTGTC 3'
K177M (kinase dead) 5' GAAAATACTATGCTATGATGATTCTGAAGAAAGAAG 3' 5' CTTCTTTCTTCAGAATCATCATAGCATAGTATTTTC 3'
25
Supplementary Table 2. Clinical and neuroimaging data of AKT3 mutation-positive patients (N=14; this series)
DB#
LR15-
262
LR16-
251
LR16-
372
LR16-
301
LR17-
100
LP96-
103
LR13-
041
LR14-
271
LR14-
254
LR12-
412
LR14-
025
LR12-
470
LR13-
008
LR14-
112
Gender M M F F M F F F F M M F M M
Ethnicity
Caucasia
n
Caucasia
n
Hispanic
Caucasia
n
Caucasia
n
Caucasia
n
Caucasia
n
Hispanic
Caucasia
n
Middle
Eastern
Caucasia
n
Hispanic
Caucasia
n
Caucasia
n
Age last
assessed
2.5m 10m 8y 21m 3y
Neonatal
period
3y 9m 8y10m 6y 26m 6y 6y10m 8y8m
Diagnosis
DMEG/
HMEG
DMEG/
Multifoc
al
MEG
MEG-
PMG-
PNH
MEG
MEG-
PMG-
PNH
MEG-
PMG
MEG-
PMG
MEG-
PMG
MEG-
PMG
MEG-
PMG
MEG
MEG-
autism
MEG-
PMG-
PNH
Birth
OFC – SD
+2 SD MEG ND +2.5
PENDIN
G
ND
MEG,
ND
+4 +2.5 ND +2 ND +2.7
Congenit
al MEG
Last OFC
– SD (age)
–2 SD MEG
+5 SD
(8y)
+6 SD
(21m)
PENDIN
G
Postnatal
MEG,
ND
+4 (3y)
+ 5.5
(9m)
+6.2
+1-2
(6y)
+5 (7m)
+7-8
(6y)
+6
+2.5
(8y8m)
Digital
anomalies
– – – – – –
Mild 2-3
toe SYN
– – –
Partial
SYN
toes 3-4
(R, L)
Promine
nt
fingertip
pads
– –
Vascular
anomalies
+ + – – – – + – + – – – + +
Connectiv
e tissue
anomalies
– + – – – + + – – – – – + –
Epilepsy + + – + – ND + – –* + + – + +
Epilepsy
onset
1h Neonatal – 4w – ND 14m – – 1y2m ND – 10h 13m
26
Epilepsy
severity
Intractab
le
Intractab
le
–
Responsi
ve to
AED
– ND
Multi
drug
resistant
epilepsy
– – ND ND – – –
Ketogenic
diet
– + – – – ND – – – ND ND – – –
Hypoglyc
emia
– + – – – ND + – – ND ND – + –
Temperat
ure issues
– ++ –
Episodes
of
hyperthe
rmia
– ND – – – ND – –
Excessiv
e
sweating
–
DD/ID NA NA
Moderat
e-severe,
non-
verbal
Severe – ND Mild
Severe
early
delays,
poor
head
control
Mild-
moderate
Motor
delays
Mild-
moderate
Mild
motor
delays,
mild
ID/LD
Mild DD
Severe
GDD, no
speech,
wheelch
air
bound
Autistic
features
NA NA + NA – ND + NA – ND – –
ASD
noted at
24-39m,
–
occasion
al self-
harming
behavior
–
Tone Normal
Severe
hypotoni
a
Infantile
hypotoni
a
Severe
hypotoni
a
Normal
Severe
hypotoni
a, poor
L
hemidyst
onia
Severe
hypotoni
a
Mild
hypotoni
a
Hypoton
ia,
Generali
zed
Normal
Generali
zed
Generali
zed
27
(improve
d),
hypotoni
c facies
head
control
floppy as
an infant
hypotoni
a
hypotoni
a
hypotoni
a
Feeding
issues
NG-tube
fed for
50% of
feeds
Breast
fed
initially,
then NG
tube fed
+ – – +
Initial
difficulti
es with
dystonia
++ – ND
Chewing
difficulti
es
–
+,
Related
to hypo-
/hyper-
glycaemi
a,
controlle
d diet
G-tube
Course
Intractab
le
epilepsy,
s/p
hemisph
erectomy
at 2w of
age
Decease
d at 10m
4d
Alive Alive Alive
Decease
d, early
childhoo
d, due to
pneumon
ia
Alive Alive Alive Alive Alive Alive Alive Alive
Abbreviations: ASD, autism spectrum disorder; DD, developmental delay; DMEG, dysplastic megalencephaly; F, female; h, hour; ID, intellectual disability; LD, learning
disability; M, male; m, month; MEG, megalencephaly; NA, not applicable; ND, no data; NG, nasogastric; PMG, polymicrogyria; PNH, periventricular nodular heterotopia; SYN,
syndactyly; TC, tonic-clonic seizures; y, year.
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Supplementary Table 3. Summary of the neuroimaging features of AKT3 mutation positive patients identified to date (N=25)
Subject ID
Amino
acid
change
Domain Type MEG MCD
Symmetr
y
VMEG
HYD
CC CBL/PF
Other MRI
findings
Diagnosis
Mosaic AKT3 mutations (N=5)
LR15-262 p.E17K PH Mosaic + FCD2 L>>R –
Thin,
dysplastic
– – DMEG/HMEG
HME-1565
(Lee et al.,
2012)
p.E17K PH Mosaic + FCD2 L>>R
VMEG,
dysplastic
ventricles
ND ND – DMEG/HMEG
Patient
3(Poduri et
al., 2012)
p.E17K PH Mosaic + FCD2 R>>L – ND – – DMEG/HMEG
LR11-
443(Jansen
et al., 2015)
p.E17K PH Mosaic + FCD2 L>>R VMEG Thin, short
CBLH
(mild)
Mild CBLH,
increased
XAX
DMEG/HMEG
LR16-251 p.E17K PH Mosaic +
FCD
(multifocal)
R=L – Thick – – DMEG/multifocal
Constitutional AKT3 mutations (by functional domain; N=20)
Patient(Tak
agi et al.,
2017)
p.E40L PH Constitutional + – R=L
VMEG
(mild)
– – – MEG
LR16-372 p.N53L PH Constitutional + – R=L – Mildly thick – – MEG
LR16-301 p.F54Y PH Constitutional +
Diffuse
PMG-PNH
R=L +++
Thick,
stretched
– CSPV MEG-PMG-PNH
LR17-XXX p.W79C PH Constitutional + – R=L – – – – MEG
LP96-103 p.V183D Kinase Constitutional +
PMG (BPP)-
PNH
R=L
VMEG
(mod)
ND –
CSPV, thin
WM
MEG-PMG-PNH
29
LR12-
314(Nellist
et al., 2015)
p.V183D Kinase Constitutional +
PMG (BPP)-
PNH
R=L
VMEG
(mild)
–
Mild
CBTE
– MEG-PMG-PNH
LR11-
354(Riviere
et al., 2012)
p.N229S Kinase Constitutional + PMG (BPP) R=L VMEG Thick
Mild
CBTE
– MEG-PMG
Patient(Har
ada et al.,
2015)
p.N229S Kinase
Presumed
constitutional
+ PMG (BPP) R=L VMEG ND – CSPV MEG-PMG
Patient
2(Nakamur
a et al.,
2014)
p.N229S Kinase Constitutional + Diffuse PMG L>>R – – – ND MEG-PMG
Patient 1
(Negishi et
al., 2014)
p.N229S Kinase Constitutional + PMG (BPP) R=L VMEG ND ND – MEG-PMG
LR13-041 p.V268A Kinase
Presumed
constitutional
+
Focal PMG
(R PS)
L>R
VMEG
(mod)
Mildly thick
Large
CBL
with mild
CBTE
CSPV MEG-PMG
LR14-271 p.D322N Kinase Constitutional +
Focal PMG
(L PS)
R=L –
Mildly thick,
dysplastic
– MEG-PMG
LR14-254 p.D322N Kinase Constitutional +
Focal PMG
(R PS)
R=L
HYD (s/p
shunt)
Thick
CBTE
s/p PF
decompr
ession
MEG-PMG
LR12-412 p.R465W C-ter Constitutional + PMG (BPP) R=L – Thick
Mild lumbar
dural ectasia
MEG-PMG
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LR14-025 p.R465W C-ter Constitutional + Diffuse PMG R=L
VMEG
(mod)
Thick
Large
CBL
CSPV,
increased
XAX
MEG-PMG
LR12-470 p.R465W C-ter
Presumed
constitutional
+
Subtle
dysgyria R
PS
R=L – Mildly thick – – MEG-autism
LR13-008 p.R465W C-ter
Presumed
constitutional
+ – R=L
VMEG
(mild)
Dysplastic,
thin splenium
–
Encephaloma
lacia and
gliosis R
insular gyrus
MEG-autism
LR14-112 p.R465W C-ter Constitutional + BPP-PVNH R=L
VMEG
(mod-severe)
Mildly thick – – MEG-PMG-PNH
LR08-
018(Riviere
et al., 2012)
p.R465W C-ter Constitutional + PMG (BPP) R=L
VMEG
(mild)
– – CSPV MEG-PMG
PMG-
3801(Jamu
ar et al.,
2014)
p.R465W C-ter Constitutional + PMG ND ND ND – ND MEG-PMG
Abbreviations: BPP, bilateral perisylvian polymicrogyria; CC, callosal abnormalities; CSPV, cavum septum pellucidum et vergae; FCD, focal cortical dysplasia; HYD,
hydrocephalus; MEG, megalencephaly; MPPH, megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome; ND, no data; PMG, polymicrogyria; PNH, periventricular
nodular heterotopia; PS, perisylvian region; VMEG, ventriculomegaly; XAX, extra-axial space.
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Supplementary Table 4. Additional pertinent medical issues in patients with AKT3 mutations
System Patient ID Summary
Endocrine problems
Hypoglycemia LR13-041 Recurrent hypoglycemia
LR13-008 Unexplained episodes of hyper- and hypo-glycaemia. Episodes occurred particularly in the morning or if diet was not monitored.
The cause of these episodes remains undetermined
Patient LR14-254 underwent a baseline endocrine evaluation which was negative
Hypothyroidism LR14-112 Hypothyroidism, treated with L-thyroxine
Vascular anomalies LR15-262 Capillary malformations
LR16-251 Patches of capillary-lymphatic malformations (~3 in number)
LR13-041 Facial nevus flammeus and prominent veins over the abdomen
LR14-254 Capillary malformations over the back, abdomen and thigh
LR13-008 Prenatal stroke due to occlusion of the right anterior coronary artery, as well as capillary malformation over a patch of aplasia cutis
of the cranium
LR14-112 Patchy capillary malformations over the palms and soles bilaterally
Connective tissue
abnormalities
LP96-103 Aplasia cutis congenita of the scalp
LR13-008 Aplasia cutis congenita of the scalp
LR13-041 Doughy skin, hypermobility
Seizures LR15-262 Child born in status epilepticus requiring early surgery. EEG at age two days showed burst suppression activity, characterized by
high amplitude bursts of spike and spike/slow wave discharges, primarily from the left hemisphere, with periods of suppressed
activity. Runs of periodic rhythmic spike and spike /slow wave discharges, occurring out of primarily left hemispheres
independently, during periods of amplitude suppression and sometimes representing electrographic seizures, suggestive of a severe
diffuse state of cerebral dysfunction and significant cerebral hyperexcitability
LR13-041 Focal symptomatic and tonic clonic seizures during sleep, plus astatic seizures, well-controlled on levetiracetam
LR14-025 A few febrile convulsions with a normal EEG
LR13-008 Focal, tonic clonic epilepsy presumed to be secondary to cerebrovascular accident, poorly controlled on trileptal
LR14-112 Complex febrile seizures with partial secondary generalization, treated with levetiracetam, valproic acid, and phenobarbital
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LR16-251 Treated with several AEDs
LR16-301 General and focal, generalized tonic-clonic seizures, controlled on several AEDs. Seizure activity on EEG. Spasm controlled on
vigabatrin and corticosteroids.
*LR14-254 EEG epileptic abnormalities including centro-temporal bilateral asynchronous slow waves, with activation during slow sleep during
the last two years of age
Other medical issues LR14-271 Failure to thrive
LR12-412 Short stature
LR14-025 Excessive oral secretions, signs of supra-bulbar palsy
LR13-008 Severe vitamin A malabsorption
LR14-112 IgA and IgE deficiency with susceptibility to severe infections
LR13-041 Recurrent infections
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Supplementary Table 5. Molecular finding, levels of mosaicism and detection method of AKT3 mutation positive patients identified to date (N=25).
Subject ID
cDNA
change
Amino acid
change
Type
Alternative allele
fraction (AAF)
Inheritance Method of detection
Mosaic AKT3 mutations
LR15-262 c.49G>A p.Glu17Lys Mosaic
0%blood, 12.6-13.9%brain,
8.6-9.5%FB
NA Multiplex PCR, NGS v.1 IonTorrent
HME-1565 (Lee
et al., 2012)
c.49C>T p.E17K Mosaic ~16-30% De novo PCR-restriction endonuclease enzyme assay
Patient 3(Poduri
et al., 2012)
c.49G>A p.Glu17Lys Mosaic
35%brain
0%blood
De novo Sanger sequencing, topo-cloning
LR11-443(Jansen
et al., 2015)
c.49G>A p.Glu17Lys Mosaic
10-18%brain, 0%dura,
10/779 (1.3%)FB
De novo MIPs, Sanger sequencing
LR16-251 c.49G>A p.Glu17Lys Mosaic 15/779 (1.8%)FB NA Targeted NGS
Constitutional AKT3 mutations
Patient(Takagi et
al., 2017)
c.118G>A p.Glu40Lys Constitutional 56/114 (49.1%)blood De novo WES
LR16-372 c.159C>A p.Asn53Leu Constitutional ~50%blood De novo
WES (singleton, with parental Sanger
confirmation)
LR16-301 c.161T>A p.Phe54Tyr Constitutional ~50%blood De novo
WES (singleton, with parental Sanger
confirmation)
LR17-XXX c.237G>T p.Trp79Cys Constitutional 492/1023 (48%) blood De novo Targeted NGS
LP96-103 c.548T>A p.Val183Asp Constitutional 291/556 (52%)blood De novoblood MIPs, Sanger sequencing
LR12-
314(Nellist et al.,
2015)
c.548T>A p.Val183Asp Constitutional 144/301 (48%)blood/FB De novo MIPs, Sanger sequencing
LR11-
354(Riviere et
al., 2012)
c.686A>G p.Asn229Ser Constitutional ~50%blood De novoblood Sanger sequencing
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Patient(Harada et
al., 2015;
Nakamura et al.,
2014)
c.686A>G p.Asn229Ser Presumed constitutional ~50%blood De novo Targeted NGS, Sanger sequencing
Patient 1
(Negishi et al.,
2014)
p.N229S Kinase Constitutional ~50%blood De novo WES
Patient
2(Nakamura et
al., 2014)
c.686A>G p.Asn229Ser Constitutional 52.5%blood De novo WES
LR13-041 c.803T>C p.Val268Ala Presumed constitutional
158/320 (49%)blood, 10/29
(34%)saliva
De novoblood,
saliva
MIPs, Sanger sequencing
LR14-271 c.964G>A p.Asp322Asn Constitutional 436/874 (50%)blood De novoblood NGS
LR14-254 c.964G>A p.Asp322Asn Constitutional ~50%saliva De novosaliva NGS (Haloplex), Sanger sequencing
LR12-412 c.1393C>T p.Arg465Trp Constitutional 50%blood NA MIPs, Sanger sequencing
LR14-025 c.1393C>T p.Arg465Trp Constitutional
50%blood
50%saliva
De novoblood,
saliva
MIPs, Sanger sequencing
LR12-470 c.1393C>T p.Arg465Trp Presumed constitutional 11/34 (32%) saliva De novosaliva MIPs, Sanger sequencing
LR13-008 c.1393C>T p.Arg465Trp Presumed constitutional 8/23 (35%)saliva De novosaliva MIPs, Sanger sequencing
LR14-112 c.1393C>T p.Arg465Trp Constitutional 50%blood, 50%saliva De novosaliva MIPs, Sanger sequencing
LR08-
018(Riviere et
al., 2012)
c.1393C>T p.Arg465Trp Constitutional 43%blood De novo WES, Sanger sequencing
PMG-
3801(Jamuar et
al., 2014)
c.1393C>T p.Arg465Trp Constitutional 22/50 (44%)blood1 De novo MIPs, Sanger sequencing
Abbreviations: FB, skin fibroblasts; NGS, next generation sequencing; MIPs, molecular inversion probes; WES, whole exome sequencing.
AKT3: NM_005465.4
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Supplementary Table 6. Fisher’s exact test comparing the association between segmental cortical malformations and the type
of AKT3 mutation (mosaic vs. constitutional).
Cohort
Segmental cortical
malformations
(FCD/HMEG)
No segmental cortical
malformations
Total
Mosaic AKT3 mutations (E17K) 5 0 5
Constitutional AKT3 mutations (all
others)
0 20 20
Total 5 20 25
The two-tailed P value <0.0001 (extremely statistically significant)
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Figure
Supplementary Figure. Proposed diagnostic workflow for individuals with megalencephaly (MEG). Individuals with
megalencephaly can be clinically stratified based on several features, including brain imaging abnormalities, into several groups
including individuals with highly focal malformations of cortical development (such as focal cortical dysplasia, FCD,
hemimegalencephaly, HMEG) caused by mosaic mutations of the PI3K-AKT-MTOR pathway (group 1); individuals with
polymicrogyria (with or without heterotopia; group 2); and individuals with diffuse megalencephaly but without the consistent cortical
dysplasia (seen more commonly in groups 1 and 2).
Notes: *Other PI3K-AKT-MTOR pathway genes (such as PTEN) may be associated with these disorders as well.
**Polymicrogyria in this group is typically bilateral perisylvian in distribution.
***This is a highly heterogeneous group of disorders that can also be associated with characteristic brain malformations in some
individuals. Several of these syndromes are also associated with somatic overgrowth (gene in bold text).
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Supplementary Text
Additional pertinent medical information:
Patient LR16-301: This child had severe hypotonia at birth. Seizures first occurred at 4 weeks of age. Infantile spasms (ISS) occurred
at 3 months of age. During the first year of life, this child was noted to have many episodes of discomfort with crying and arching of
the back. She also had episodes of suspected high intracranial pressure (ICP). Furthermore, this child had episodes of hyperthermia of
unexplained etiology. The first episode lasted 4 weeks and was partially responsive to Propranolol. This child has global
developmental delays. She is non-verbal. She recognizes family members and is fond of patterns and music. She eats a general diet by
mouth and has been growing well. The episodes of discomfort have decreased dramatically during the second year of life.
Patient LR14-025: This child walked at 20 months of life. He has delayed speech and is non-verbal at 20 months of age.
Patient LR12-470: This girl has mild/borderline intellectual disability with communicative disability that did not meet classic criteria
for Autism Spectrum Disorder (ASD). She also has significant behavioral issues with temper tantrums and sleep difficulties as well.
Patient LR13-008: This child walked at approximately 18 months of age. He had no speech development. Cognitive assessments
around 5 years of age identified his cognitive level to be 18 months of age. His eye contact deteriorated around 2.5 years of age and he
was formally diagnosed with Autism Spectrum Disorder (ASD).
Patient LR16-251: This child passed away due to complications from chronic intractable epilepsy. At 10 months of age, he had
progressive feeding intolerance requiring a reduction in his feeding volumes.
Patient LR14-254: Psychomotor delays. At 24 months, His Griffiths Mental Development scale (GQ) was 62. At 6 years of age, his
WPPSI-III scores were as follows: QIT= 92, QIV=94, QIP=100.
Patient LR08-018: This boy was born at 38 weeks of gestation because of maternal hypertension. Delivery was by Cesarean section
because of failure-to-progress. His birth weight was 8 pounds, 3 ounces, and his OFC was 38.5 cm (+2.5 standard deviations, SD). His
Apgar scores were 9 and 9. He was followed closely after discharge because of his large head size and found to have a mildly weak
suck, hypotonia, and subtle right-sided tremors that were not associated with epileptic discharges on EEG. Brain imaging studies -
serial ultrasound, head CT and brain MRI - showed large brain, enlarged but asymmetric ventricles and a cortical malformation that
appeared more extensive on the left side. A small vascular malformation was seen beneath his umbilicus.
By age 3 months, he had intermittent stridor, gastroesophageal reflux, constipation, and rapidly enlarging head size. Throughout his
first years of life, his head grew rapidly with his OFC measured at +4 SD by 3 months, +5 SD by 5 months, and +6 SD by 11 months
of age. Serial brain imaging studies revealed hydrocephalus and mild cerebellar tonsils herniation (not quite Chiari malformation) and
a shunt was placed at 11 months of age. His parents thought that his development improved after the shunt.
Examination showed a markedly enlarged head with prominent forehead and prominent small veins over his forehead, mildly deep-set
eyes, wide and prominent forehead, prominent fleshy soft tissues of his face, high-arched palate, everted lower lip and prominent
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dimple. His skin felt soft and doughy suggesting a subtle connective tissue dysplasia. He had mildly diminished movements and
increased tone on his right side.
By age 3 years, he had made some developmental progress. He had had two short seizures. He was non-verbal but could use
communicate by touching pictures on a computer screen. By 4 years, he could walk, use about 20 single words, and follow simple
commands. He also had onset of seizures that became progressively more frequent and severe. These included series of myoclonic
jerks lasting up to 30 minutes, asymmetric generalized tonic-clonic seizures that were more severe on his right side and lasted 1-5
minutes, and a few episodes of unresponsiveness lasting 5-8 minutes. Most occurred in the morning soon after waking, often with an
aura as he would walk toward his parents just before they began. Trials of multiple seizure medications had little effect, but the
ketogenic diet reduced seizure frequency to 1-2 per week.
In the weeks before his death, his seizure frequency had increased but he was otherwise healthy. On the day before his death he went
to sleep at his usual time and was seen breathing normally in the late evening. His parents found him unresponsive and not breathing
but still warm early the following morning, and he could not be resuscitated. While the terminal event was not witnessed, his history
of intractable epilepsy and recent increase in seizures suggest sudden unexpected death in epilepsy (SUDEP).
His growth measurements throughout life were the following:
Age Size (cm) Size (SD)
Birth 38.5 cm +1.63
2.5 months 46 cm +4.2
4 months 47.5 +4.5
5 months 49.5 +5.25
11 months 54 +6
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